Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic SteatohepatitisNdufexor (LMB763),一种用于治疗非酒精性脂肪性肝炎的新型FXR调节剂JOURNAL OF MEDICINAL CHEMISTRYIF6.82020-01-1585OAAI
Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in RodentsHEPATOLOGY COMMUNICATIONSIF4.62019-05-1780OAAI
LJN452 (tropifexor) attenuates steatohepatitis, inflammation, and fibrosis in dietary mouse models of nonalcoholic steatohepatitisJOURNAL OF HEPATOLOGYIF332018-04-013PREAI
Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)JOURNAL OF MEDICINAL CHEMISTRYIF6.82017-12-08209OA
Development of LMB763, a novel, orally bioavailable, clinical farnesoid X receptor agonist for the treatment of non-alcoholic steatohepatitis and hepatobiliary disordersJOURNAL OF HEPATOLOGYIF332017-01-012PREAI
Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese miceHEPATOLOGYIF15.82005-08-01284OAAI
Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonismDIABETESIF7.52005-06-01119OAAI
Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetesJOURNAL OF CLINICAL INVESTIGATIONIF13.62001-01-15206OA
Adenosine formed by 5′-nucleotidase mediates tubuloglomerular feedbackJOURNAL OF CLINICAL INVESTIGATIONIF13.62000-07-15149OA
Temporal adjustment of the juxtaglomerular apparatus during sustained inhibition of proximal reabsorptionJOURNAL OF CLINICAL INVESTIGATIONIF13.61999-10-1556OA